Table 4.
Univariate and multivariate OS analyses
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | ||
| Elderly | 0.932 | 0.536–1.621 | 0.803 | ||||
| Male | 1.922 | 0.910–4.060 | 0.130 | ||||
| Reduced BMI | 2.064 | 1.084–3.931 | 0.028* | Reduced BMI | 1.982 | 0.995–3.950 | 0.052 |
| HBV related | 1.461 | 0.848–2.516 | 0.172 | ||||
| HCV related | 0.804 | 0.417–1.550 | 0.515 | ||||
| ALBI grade >1 | 3.262 | 1.931–5.509 | <0.001* | ALBI grade >1 | 2.711 | 1.565–4.695 | <0.001* |
| MELD score | 1.108 | 1.018–1.207 | 0.017* | MELD score | 1.131 | 1.020–1.254 | 0.019* |
| Size >5 cm | 1.363 | 0.792–2.346 | 0.263 | ||||
| Number >5 | 1.349 | 0.790–2.305 | 0.273 | ||||
| Bilobar | 0.774 | 0.466–1.287 | 0.323 | ||||
| AFP >400 ng/mL | 2.603 | 1.551–4.371 | <0.001* | AFP >400 ng/mL | 1.525 | 0.834–2.789 | 0.170 |
| BCLC stage C | 1.978 | 1.184–3.305 | 0.009* | BCLC stage C | 0.860 | 0.639–1.158 | 0.320 |
| ECOG performance status 1 | 1.946 | 0.954–3.969 | 0.067 | ||||
| Prior therapy | 0.666 | 0.392–1.132 | 0.133 | ||||
| 4-month objective response | 0.431 | 0.257–0.724 | <0.001* | 4-month objective response | 0.464 | 0.265–0.812 | 0.007* |
| Posttreatment curative therapy | 0.283 | 0.141–0.568 | <0.001* | Posttreatment curative therapy | 0.405 | 0.187–0.877 | 0.022* |
| TAM-defined sarcopenia | 1.070 | 0.603–1.897 | 0.817 | ||||
| PM-defined sarcopenia | 1.735 | 1.036–2.903 | 0.036* | PM-defined sarcopenia | 1.899 | 1.087–3.315 | 0.024* |
| PS-defined sarcopenia | 0.574 | 0.179–1.842 | 0.351 | ||||
HR, hazard ratio; CI, confidence interval; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI, albumin-bilirubin; MELD, Model for End-Stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; TAM, total abdominal muscle; PM, psoas muscle; PS, paraspinal muscle.
*p < 0.05.